Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
作者： Hyun-Ah Kim , Min-Ki Seong , Eun-kyu Kim , Eunyoung Kang , Seho Park
DOI: 10.4048/JBC.2015.18.3.271
关键词:
摘要: PURPOSE: This study aimed to evaluate the survival benefit of different adjuvant chemotherapy regimens in patients with T1-2N0 triple-negative breast cancer. METHODS: Of 67,321 who were registered Korean Breast Cancer Society nationwide database between January 1999 and December 2008, 4,033 cancer included. The overall did not receive was compared those treated anthracycline cyclophosphamide (AC), 5-fluorouracil, anthracycline, (FAC), or cyclophosphamide, methotrexate, 5-fluorouracil (CMF). RESULTS: median follow-up 52.5 months. Chemotherapy used 87.4% patients; it more commonly T2 tumors, younger, had a higher histologic grade, showed lymphovascular invasion. 5-year cumulative rate 95.4%. Younger age, breast-conserving surgery, significantly associated improved survival. AC, FAC, CMF 92.5%, 95.9%, 95.3%, respectively. On multivariate analysis, administration any regimen (p=0.038). No significant difference observed among three treatment groups. CONCLUSION: A standard least drug-related toxicity might be reasonable for cancer.
sci-hub.se 参考文章(29)
Aymen Lagha, Nesrine Chraiet, Soumaya Labidi, Sarra Krimi, Mouna Ayadi, Joseph Gligorov, Hamouda Boussen, Place des taxanes en adjuvant dans le traitement des cancers du sein sans envahissement ganglionnaire Bulletin Du Cancer. ,vol. 100, pp. 465- 471 ,(2013) , 10.1684/BDC.2013.1743
Altundag K, Zengin N, Ozdemir N, Aksoy S, Taxanes in the adjuvant treatment of node-negative breast cancer patients. Journal of B.U.ON. : official journal of the Balkan Union of Oncology. ,vol. 17, pp. 27- 32 ,(2012)
Muaiad Kittaneh, Alberto J. Montero, Stefan Glück, Molecular profiling for breast cancer: a comprehensive review. Biomarkers in Cancer. ,vol. 5, pp. 61- 70 ,(2013) , 10.4137/BIC.S9455
Early Breast Cancer Trialists' Collaborative Group, None, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet. ,vol. 379, pp. 432- 444 ,(2012) , 10.1016/S0140-6736(11)61625-5
Alice Y Ho, Gaorav Gupta, Tari A King, Carmen A Perez, Sujata M Patil, Katherine H Rogers, Yong Hannah Wen, Edi Brogi, Monica Morrow, Clifford A Hudis, Tiffany Traina, Beryl McCormick, Simon N Powell, Mark E Robson, None, Favorable prognosis in patients with T1a/T1bN0 triple‐negative breast cancers treated with multimodality therapy Cancer. ,vol. 118, pp. 4944- 4952 ,(2012) , 10.1002/CNCR.27480
Bernard Fisher, Stewart Anderson, Elizabeth Tan-Chiu, Norman Wolmark, D Lawrence Wickerham, Edwin R Fisher, Nikolay V Dimitrov, James N Atkins, Neil Abramson, Sofia Merajver, Edward H Romond, Carl G Kardinal, Henry R Shibata, Richard G Margolese, William B Farrar, None, Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23 Journal of Clinical Oncology. ,vol. 19, pp. 931- 942 ,(2001) , 10.1200/JCO.2001.19.4.931
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Lisa Carey, Eric Winer, Giuseppe Viale, David Cameron, Luca Gianni, Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology. ,vol. 7, pp. 683- 692 ,(2010) , 10.1038/NRCLINONC.2010.154
Adam J. Olszewski, Yazan Migdady, Susan K. Boolbol, Paula Klein, Kwadwo Boachie-Adjei, Bachir J. Sakr, William Sikov, Theresa Shao, Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study Breast Cancer Research and Treatment. ,vol. 138, pp. 215- 223 ,(2013) , 10.1007/S10549-013-2423-3
I.C. Henderson, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (Clinical Trial Service Unit (CTSU), Oxford, UK) Lancet 379:432-444, 2012§ Breast Diseases: A Year Book Quarterly. ,vol. 24, pp. 76- 78 ,(2013) , 10.1016/J.BREASTDIS.2013.01.026